Floatz logo

Ruxolitinib

Stem Cell Transplant

Bambino Gesù Hospital and Research InstituteSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Stem Cell Transplant cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Bambino Gesù Hospital and Research Institute
Phase 2/3B
Rapamycin
University of California, San Francisco
Phase 2CCC

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →